InVivo Therapeutics appoints interim CEO, Reynolds resigns
This article was originally published in Scrip
Executive Summary
Francis M Reynolds has resigned as chair, chief executive officer and chief financial officer of InVivo Therapeutics due to an unreported medical condition. The Cambridge, Massachusetts-based company's board has appointed Michael J Astrue and Sean Moran as CEO and CFO, respectively. Mr Astrue is currently the non-executive chair of the board at drug development company Vivus. InVivo develops treatments to improve function in individuals paralyzed from traumatic spinal cord injuries.